On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Salesforce has become more profitable in the past few years, but one activist investor says there’s more for the software ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Read about activist investor Starboard Value's bullish outlook on Salesforce's valuation and potential to exceed the Rule of ...

Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...